Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 5/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16571010 | 0.85 | KIF11 (0.43) | KIF11MAPK1PTK2PTK2BULK1 | |
| SCHEMBL16570966 | 0.82 | KIF11 (0.43) | KIF11MAPK1PTK2PTK2BULK1 | |
| SCHEMBL16571152 | 0.80 | MAPK1 (0.44) | MAPK1 | |
| SCHEMBL16570815 | 0.80 | KIF11 (0.43) | KIF11MAPK1PTK2PTK2BULK1 | |
| SCHEMBL16571125 | 0.80 | IRAK4 (0.41) | MAPK1 | |
| SCHEMBL16570659 | 0.79 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL16570523 | 0.79 | PTK2 (0.58) | KIF11MAPK1PTK2PTK2B | |
| SCHEMBL16570701 | 0.77 | ULK1 (0.47) | KIF11PTK2PTK2BULK1 | |
| SCHEMBL16570151 | 0.74 | ULK1 (0.47) | KIF11PTK2PTK2BULK1 | |
| SCHEMBL16570824 | 0.74 | KIF11 (0.47) | KIF11PTK2PTK2BULK1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | claimed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | claimed |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | disclosed |
| US-20150175545-A1 | Preparation Method of Fluoro-Substituted Deuterated Diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD (CN) | 2015-06-25 | — | — | US | disclosed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | KIF11 3206/4885MAPK1 96/4885PTK2 2/4885 |
| US-20150175545-A1 | Preparation Method of Fluoro-Substituted Deuterated Diphenylurea | CCND3, UBE2D3, VDR | KIF11 2130/4885MAPK1 4581/4885PTK2 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.